Expression of bone morphogenetic protein in the course of osteoinduction by recombinant human bone morphogenetic protein-2.
To clarify the mechanism of osteoinduction by recombinant human bone morphogenetic protein-2 (rhBMP-2), we examined the time-course localization of bone morphogenetic proteins (BMPs) immunostained by an anti-BMP-2 monoclonal antibody after implantation of pellets consisting of rhBMP-2 and collagen in rat calf muscle pouch. On day 3 after implantation, BMP was detected in the entire lump, and the intensity of staining for BMP around the implant on day 7 was weaker than that on day 3. The staining for BMP decreased with time and the region of staining for BMP remained more centralized in the implant. On day 10 after implantation, BMP was observed in part of the newly induced cartilage, especially around chondrocytes. On day 14 after implantation, BMP was localized in the newly induced woven bone. On day 21, BMP staining was found in osteoblasts at the surface of the newly induced bone. Especially, the staining for BMP decreased from day 10 to day 21. These results indicate that the woven bone was replaced with mature lamellar bone from day 14 to day 21. The present findings suggest that rhBMP-2 plays an important role in osteoinduction, especially at the early stage.
Okubo
Yasunori
Y
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Shogoin, Japan. okubo@kuhp.kyoto-u.ac.jp
Bessho
Kazuhisa
K
Fujimura
Kazuma
K
Kusumoto
Kenji
K
Ogawa
Yutaka
Y
Iizuka
Tadahiko
T
D000818:Animals; D000911:Antibodies, Monoclonal; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000032:analysis / Q000494:pharmacology*; D001842:Bone and Bones / Q000473:pathology; D002356:Cartilage / Q000473:pathology; D019902:Chondrocytes / Q000473:pathology; D003094:Collagen / Q000032:analysis / Q000494:pharmacology; D004396:Coloring Agents; D004343:Drug Implants; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008648:Mesoderm / Q000473:pathology; D018482:Muscle, Skeletal / Q000473:pathology; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004396:Coloring Agents; D004343:Drug Implants; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D003094:Collagen